Bristol-Myers Squibb Company
COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
Last updated:
Abstract:
Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.
Status:
Application
Type:
Utility
Filling date:
30 May 2018
Issue date:
4 Nov 2021